Clinical trial registry record

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 26, 2009.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00559715
Last registry update
March 26, 2009
Status
Unknown
Phase
Phase 3
Sponsor
Klinikum Bremen-Mitte, gGmbH
Enrollment
366
Countries
Germany
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
366
Population
ALL · 50 Years
Duration
2008-08-01 to 2010-08-01
Intervention
bevacizumab; ranibizumab
Comparator
B
Outcomes measured
Proportion of patients with a loss of fewer than 15 letters at month 12 — 1 year; Proportion of patients with a loss of fewer than 15 letters at month 24 — 2 years; Mean change from baseline in BCVA at month 12 (IA) and month 24 — 2 years; Proportion of patients with a treatment-free interval of at least 3 months' duration at any time point following month…; Number of doses of the study drugs — 2 years; Drop out rates — 2 years; Rate of non-responders — 2 years; Retinal lesions — 2 years; Adverse Events — 2 years; Quality of Life — 2 years
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON